drugset
Drugs / REACT
last change Dec 2023 re-read 3 minutes ago

REACT

Cell therapy

Developed for
chronic kidney disease · type 2 diabetes mellitus
Investigated by
CTI Clinical Trial and Consulting Services · Prokidney

Trials 1

today NCT02836574 · Ph 2
20172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT02836574 Sep 2016 → Dec 2023 chronic kidney disease, type 2 diabetes mellitus Prokidney Completed No outcome recorded

Press releases naming this drug 10 releases

DateIssuerRelease
2023-11-13 Prokidney ProKidney Announces Positive Interim Data from RMCL-002 Phase 2 Clinical Trial of Renal Autologous Cell Therapy (REACT®) for Diabetic CKD and Provides Corporate Updates prokidney.com ↗
2023-01-10 Prokidney ProKidney Announces Publication of Trial Design for Phase 2 Multicenter Clinical Trial of REACT for Late Stage 4 Diabetes-Related Chronic Kidney Disease prokidney.com ↗
2022-11-03 Prokidney ProKidney Receives Allowance from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for proact 1 (REGEN-006) and EMA Scientific Advice on Phase 3 Protocols of REACT for Diabetic Chronic Kidney Disease prokidney.com ↗
2022-06-23 Prokidney ProKidney Corroborates the Mechanism of Action of REACT™ with Cell Marker Analysis in Patients with Diabetic Chronic Kidney Disease prokidney.com ↗
2022-06-15 Prokidney ProKidney Announces Manufacturing Efficiency Initiatives and Supply Chain Streamlining Expected to Reduce REACT™ Manufacturing Costs prokidney.com ↗
2022-06-07 Prokidney Observed Safety Profile Supports Bilateral Dosing of ProKidney’s REACT™ – 007 Update prokidney.com ↗
2022-05-03 Prokidney ProKidney highlights key registrational program elements supporting advancement of REACT® prokidney.com ↗
2022-04-12 Prokidney ProKidney confirms Phase 3 program for autologous kidney cell therapy REACT® prokidney.com ↗
2022-03-01 Prokidney ProKidney to Present REACT® at 4th Annual CKD Summit prokidney.com ↗
2022-01-27 Prokidney ProKidney Announces Online Publication of Trial Design for Phase II Multicenter Clinical Trial of REACT® Autologous Cell Therapy for Treatment of Chronic Kidney Disease prokidney.com ↗

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as REACT ClinicalTrials.gov intervention name — accepted as the source's own label NCT02836574 ↗
Modality Cell therapy “novel renal autologous cell therapy (REACT)” PMID 35034024 ↗ Jan 2022
Route Other “by direct kidney parenchymal injection via the percutaneous approach” PMID 35034024 ↗ Jan 2022